PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non–Small Cell Lung Cancer Patients with Malignant Pleural Effusion
- 1 March 2018
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 13 (3), 447-453
- https://doi.org/10.1016/j.jtho.2017.10.034
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia StudyJournal of Clinical Oncology, 2016
- Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung CancerJournal of Thoracic Oncology, 2015
- Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategiesAnnals Of Oncology, 2015
- Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancerAnnals Of Oncology, 2014
- Preoperative BRAF(V600E) mutation screening is unlikely to alter initial surgical treatment of patients with indeterminate thyroid nodules: A prospective case series of 960 patientsCancer, 2013
- Adoptive Transfer of Immunomodulatory M2 Macrophages Prevents Type 1 Diabetes in NOD MiceDiabetes, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerThe New England Journal of Medicine, 2012
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 ExpressionClinical Cancer Research, 2004
- Elevation of Interleukin-10 Levels in Malignant Pleural EffusionSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1996